Stanley Bergman Sells 10,785 Shares of Henry Schein (NASDAQ:HSIC) Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 10,785 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $81.20, for a total value of $875,742.00. Following the completion of the sale, the chief executive officer directly owned 309,092 shares of the company’s stock, valued at approximately $25,098,270.40. The trade was a 3.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Henry Schein Stock Performance

NASDAQ HSIC traded up $0.92 on Friday, hitting $82.39. 1,562,469 shares of the stock were exchanged, compared to its average volume of 1,447,010. The company has a market capitalization of $9.70 billion, a PE ratio of 25.20, a P/E/G ratio of 2.43 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.79. The business’s fifty day moving average is $77.75 and its 200 day moving average is $72.04. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. Henry Schein’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Institutional Trading of Henry Schein

Institutional investors and hedge funds have recently modified their holdings of the business. MAI Capital Management lifted its holdings in shares of Henry Schein by 7.5% in the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after acquiring an additional 144 shares during the last quarter. CW Advisors LLC lifted its stake in Henry Schein by 2.8% in the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after purchasing an additional 163 shares during the last quarter. Truist Financial Corp grew its stake in shares of Henry Schein by 3.3% during the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after buying an additional 175 shares during the last quarter. Simon Quick Advisors LLC grew its stake in shares of Henry Schein by 5.5% during the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after buying an additional 182 shares during the last quarter. Finally, Claret Asset Management Corp increased its holdings in shares of Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after buying an additional 187 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HSIC has been the topic of a number of research analyst reports. Robert W. Baird set a $100.00 price target on Henry Schein and gave the company an “outperform” rating in a research note on Monday. Wells Fargo & Company upped their target price on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday. Barrington Research set a $97.00 price objective on Henry Schein and gave the company an “outperform” rating in a report on Wednesday. Evercore boosted their target price on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Finally, Barclays started coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.